ReviewBiomedicines2020
Advances in Cardiovascular Biomarker Discovery.
Review in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 65 citations in OpenAlex.
- The diagnostic value of miR-1299 in acute myocardial infarction.Journal of cardiothoracic surgery · 2026Article
- Biomarkers in Disease Diagnosis and Monitoring: Insights into Clinical Applications and Mass Spectrometry-based Detection.Applied biochemistry and biotechnology · 2026Review
- Advancements in Biomarkers for Early Detection and Risk Stratification of Cardiovascular Diseases-A Literature Review.Health science reports · 2025Article
- A multidimensional approach to assess cardiovascular disease risk combining biochemical, hematological, lipid ratios, atherosclerotic cardiovascular disease, and WHO/ISH 10-year risk estimators: a cross-sectional study.American journal of cardiovascular disease · 2025Article
- Development and validation of a machine learning model for online predicting the risk of in heart failure: based on the routine blood test and their derived parameters.Frontiers in cardiovascular medicine · 2025Article
- Evaluation of Pro-BNP biomarker in heart failure patients and its relationship with complete blood count parameters: A case-control study.Health science reports · 2024Article
- Revolutionary Point-of-Care Wearable Diagnostics for Early Disease Detection and Biomarker Discovery through Intelligent Technologies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Automated Data Transformation and Feature Extraction for Oxygenation-Sensitive Cardiovascular Magnetic Resonance Images.Journal of cardiovascular translational research · 2024Article
- MEK inhibitors: a promising targeted therapy for cardiovascular disease.Frontiers in cardiovascular medicine · 2024Review
- Diagnostic and prognostic value of miR-486-5p, miR-451a, miR-21-5p and monocyte to high-density lipoprotein cholesterol ratio in patients with acute myocardial infarction.Heart and vessels · 2023Article
- Review
- Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases.Heliyon · 2023Review
- Current Nanomedicine for Targeted Vascular Disease Treatment: Trends and Perspectives.International journal of molecular sciences · 2022Review
- Evaluation of Circulating MicroRNAs and Adipokines in Breast Cancer Survivors with Arm Lymphedema.International journal of molecular sciences · 2022Article
- Cardiovascular Disease Diagnosis from DXA Scan and Retinal Images Using Deep Learning.Sensors (Basel, Switzerland) · 2022Article
- Application of omics in hypertension and resistant hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation.Journal of personalized medicine · 2022Article
- A History of Preterm Delivery Is Associated with Aberrant Postpartal MicroRNA Expression Profiles in Mothers with an Absence of Other Pregnancy-Related Complications.International journal of molecular sciences · 2021Article
- Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and its pathological complications pose a major risk for the development of other cardiovascular diseases, including heart failure and stroke. Identifying novel and early stage biomarkers of hypertension and other cardiovascular diseases is of paramount importance in predicting and preventing the major morbidity and mortality associated with these diseases. Biomarkers of such diseases or predisposition to their development are identified by changes in a specific indicator's expression between healthy individuals and patients. These include changes in protein and microRNA (miRNA) levels. Protein profiling using mass spectrometry and miRNA screening utilizing microarray and sequencing have facilitated the discovery of proteins and miRNA as biomarker candidates. In this review, we summarized some of the different, promising early stage protein and miRNA biomarker candidates as well as the currently used biomarkers for hypertension and other cardiovascular diseases. Although a number of promising markers have been identified, it is unlikely that a single biomarker will unambiguously aid in the classification of these diseases. A multi-marker panel-strategy appears useful and promising for classifying and refining risk stratification among patients with cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.